Financials

	2022	2023
Net sales	54.13M 46.64M 43.73M 39.92M 75.21M 5.17B 75.45M 519M 202M 2.61B 203M 199M 8.66B	80.75M 69.59M 65.24M 59.56M 112M 7.72B 113M 774M 302M 3.9B 303M 297M 12.92B
Net income	-18.11M -15.6M -14.63M -13.35M -25.16M -1.73B -25.24M -174M -67.72M -874M -67.98M -66.5M -2.9B	-20.13M -17.35M -16.27M -14.85M -27.97M -1.92B -28.06M -193M -75.29M -971M -75.59M -73.94M -3.22B
Net Debt	42.09M 36.27M 34.01M 31.04M 58.48M 4.02B 58.67M 403M 157M 2.03B 158M 155M 6.73B	55.34M 47.69M 44.71M 40.82M 76.89M 5.29B 77.13M 530M 207M 2.67B 208M 203M 8.85B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq 23:00:00 13/09/2024 +03			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 260M 243M 222M 419M 28.8B 420M 2.89B 1.13B 14.54B 1.13B 1.11B 48.2B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 307M 288M 263M 495M 34.08B 497M 3.42B 1.33B 17.21B 1.34B 1.31B 57.05B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/09/24	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/09/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/09/24	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
10/09/24	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/08/24	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/07/24	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/06/24	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/06/24	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/06/24	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/06/24	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/03/24	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation : Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations : Alimera Sciences, Inc.

Press Releases : Alimera Sciences, Inc.

News in other languages : Alimera Sciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/16/24 A	Margaret Pax	Issuer sale	Director	36,713	0.0675%
9/16/24 A	Velan Capital Investment Management LP	Issuer sale	Company	14,408,533	26.4940%
9/16/24 A	David Holland	Issuer sale	Chief Marketing Officer & SVP	1,232,852	2.2669%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+59.20%	287M
REGENERON PHARMACEUTICALS, INC.	-1.67%	-4.78%	+36.76%	-4.88%	79.3B
CSL LIMITED	-0.36%	+1.51%	-18.36%	-37.24%	59.21B
MODERNA, INC.	-3.35%	-4.92%	+472.81%	+18.32%	55.09B
SAMSUNG BIOLOGICS CO.,LTD.	-6.78%	-4.19%	-3.45%	+28.01%	49.86B
UCB	-2.43%	-2.35%	+8.33%	+163.57%	47.9B
BIOGEN INC.	-1.35%	+0.79%	+65.25%	-18.22%	32.28B
INCYTE CORPORATION	-2.64%	-2.69%	+46.99%	+90.61%	25.21B
INNOVENT BIOLOGICS, INC.	-0.09%	+4.98%	+11.00%	+199.03%	23.87B
SWEDISH ORPHAN BIOVITRUM AB	-0.34%	+1.35%	+62.33%	+125.87%	16.89B
Average	-1.92%	-1.08%	+68.17%	+62.43%	38.99B
Weighted average by Cap.	-2.34%	-2.05%	+83.89%	+41.65%

3 years	2.61	5.65
5 years	1.3	7.92
10 years	0	25.8